Treatment_of_acute_myeloid_leukaemia_in_a_renal_allograft_recipient:_implications_of_cyclosporin_immunosuppressive_treatment._The_clinical_effects_of_cyclosporin_were_evaluated_during_cytotoxic_treatment_in_a_61_year_old_man_with_acute_myeloid_leukaemia._He_had_required_a_renal_transplant_18_months_before_presenting_with_acute_myeloid_leukaemia_(FAB_subtype_M4)._He_had_received_cyclosporin_3.5-4.0_mg/kg_daily_to_maintain_a_plasma_cyclosporin_concentration_of_75-150_ng/ml._Cyclosporin_was_continued_during_induction_chemotherapy_with_daunorubicin,_cytarabine,_and_6-thioguanine_(DAT)._He_had_fever_and_oropharyngeal_candidiasis_that_was_unresponsive_to_anti-bacterial_drugs_but_responsive_to_systemic_amphotericin._Bone_marrow_examination_14_days_after_chemotherapy_showed_complete_haematological_remission._Subsequently_he_tolerated_consolidation_treatment_with_DAT_with_no_serious_complications._Unfortunately_he_developed_fatal_septicaemia_following_a_second_consolidation_with_mitozantrone_and_cytarabine._Inhibition_of_P-glycoprotein_activity_by_cyclosporin_may_not_significantly_increase_the_toxicity_of_aggressive_chemotherapeutic_regimens,_and_as_benefit_may_be_achieved_by_this_approach_further_clinical_evaluation_is_justified.